High-level primary CD8(+) T-cell response to human immunodeficiency virus type 1 gag and env generated by vaccination with recombinant vesicular stomatitis viruses.
about
Multimeric soluble CD40 ligand and GITR ligand as adjuvants for human immunodeficiency virus DNA vaccines.Kunjin Virus Replicon Vectors for Human Immunodeficiency Virus Vaccine DevelopmentHybrid alphavirus-rhabdovirus propagating replicon particles are versatile and potent vaccine vectorsObstacles to the successful development of an efficacious T cell-inducing HIV-1 vaccine.Potent vesicular stomatitis virus-based avian influenza vaccines provide long-term sterilizing immunity against heterologous challenge.A single-cycle vaccine vector based on vesicular stomatitis virus can induce immune responses comparable to those generated by a replication-competent vector.A vesicular stomatitis virus recombinant expressing granulocyte-macrophage colony-stimulating factor induces enhanced T-cell responses and is highly attenuated for replication in animalsRobust recall and long-term memory T-cell responses induced by prime-boost regimens with heterologous live viral vectors expressing human immunodeficiency virus type 1 Gag and Env proteinsMatrix protein mutant of vesicular stomatitis virus stimulates maturation of myeloid dendritic cellsVesicular stomatitis virus as a vector to deliver virus-like particles of human norovirus: a new vaccine candidate against an important noncultivable virus.Nonsegmented negative-strand viruses as vaccine vectors.Development of a novel surrogate virus for human T-cell leukemia virus type 1: inhibition of infection by osteoprotegerin.A duck enteritis virus-vectored bivalent live vaccine provides fast and complete protection against H5N1 avian influenza virus infection in ducks.Utility of the aged BALB/c mouse model to demonstrate prevention and control strategies for severe acute respiratory syndrome coronavirus (SARS-CoV)DNA vaccines against human immunodeficiency virus type 1 in the past decade.Vesicular stomatitis virus-based therapeutic vaccination targeted to the E1, E2, E6, and E7 proteins of cottontail rabbit papillomavirusFirst-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Vesicular Stomatitis Virus Human Immunodeficiency Virus-1 gag Vaccine (HVTN 090).The immune response to a vesicular stomatitis virus vaccine vector is independent of particulate antigen secretion and protein turnover rate.Intranasal delivery of vaccines against HIV.Attenuation of recombinant vesicular stomatitis virus-human immunodeficiency virus type 1 vaccine vectors by gene translocations and g gene truncation reduces neurovirulence and enhances immunogenicity in miceEnhancement of gp120-specific immune responses by genetic vaccination with the human immunodeficiency virus type 1 envelope gene fused to the gene coding for soluble CTLA4.Functional human immunodeficiency virus type 1 (HIV-1) Gag-Pol or HIV-1 Gag-Pol and env expressed from a single rhabdovirus-based vaccine vector genome.Complete protection from papillomavirus challenge after a single vaccination with a vesicular stomatitis virus vector expressing high levels of L1 protein.Single-dose, therapeutic vaccination of mice with vesicular stomatitis virus expressing human papillomavirus type 16 E7 protein.Recombinant vesicular stomatitis virus expressing influenza nucleoprotein induces CD8 T-cell responses that enhance antibody-mediated protection after lethal challenge with influenza virus.Intranasal immunization with recombinant vesicular stomatitis virus expressing murine cytomegalovirus glycoprotein B induces humoral and cellular immunity.Characterization of nonpathogenic, live, viral vaccine vectors inducing potent cellular immune responses.Intramuscular immunization with a vesicular stomatitis virus recombinant expressing the influenza hemagglutinin provides post-exposure protection against lethal influenza challenge.Vesicular Stomatitis Virus-Vectored Multi-Antigen Tuberculosis Vaccine Limits Bacterial Proliferation in Mice following a Single Intranasal DoseVSV-GP: a potent viral vaccine vector that boosts the immune response upon repeated applications.RNA-based viral vectors.Current prospects and future challenges for nasal vaccine delivery.
P2860
Q27472925-E2397C45-3589-447D-AFF5-2EF15700E2DAQ27477561-39940E8E-0BEA-46C0-B9D0-6626156392B7Q27485876-C10B1505-40D7-4971-83AE-49AF08801710Q30378897-62057A80-F9F9-40DD-953F-683F4FA7D0D9Q30385999-77B702D8-C2EE-4D4D-8A36-F8157A3807EDQ34092753-E36035EF-0A60-496D-BC12-97D0FAE8A60FQ34228558-E87AE08C-F255-4E19-A3AA-D49E72228DD8Q34343020-EF2F19C4-C0AF-450F-987F-A950981BC538Q34434660-BE0BF732-3ADC-4BCA-B7DA-7674A58030FBQ34742846-F8E8588E-EBA9-4CF1-8816-C2CD049B6D15Q35139219-6753C9D9-388A-4A37-83BD-D7A29C89942DQ35155045-C118FC84-0F57-4AB2-AC7B-6934641813D8Q35363479-12E6D425-B1EE-42A9-83EE-FE1297938593Q35740733-A61982A1-EDAF-4693-8E3A-F315278387A2Q35745831-22F6484D-2544-4AA7-82DA-9C57295B2A04Q35857789-BC37844A-EE75-4383-9289-EAACF37CD9C5Q35858437-839E7947-D390-47EA-A049-3F57B9CBCBD3Q35867988-1855079B-058B-4E4F-A90E-96FBC6A0F8F6Q36409054-80F6455D-E823-44EA-9E65-FDFA2BF41C05Q36423935-6E4B1299-29AC-4245-B966-2128E84B4502Q36473515-14433E34-F8D4-4912-A16C-0ECD4F69D980Q36474235-B13969E1-7EEA-40C4-87D4-FF7BA797E14CQ36509916-F8D07BCF-1EA2-4D98-B858-304238B5FC80Q36672543-7FF7913D-7A15-4E5C-B976-92BFC1B4E909Q37156713-B38C1A98-2BF9-499B-A20B-D2AF6F7F64F8Q37243886-52328A76-60A7-46F2-9E28-44D732DA4E24Q37348721-D4B55003-B399-41D8-980A-5C31067403C8Q37455765-40A208CE-A09B-4FC9-BC2D-43D66FDEEB2CQ37627029-BBA50E1C-FE3A-4AAD-ABBC-552487F36775Q37714030-12800035-3FF0-4754-81B5-27733BD1B843Q38266413-F14305D4-409B-4FB1-A528-98DC4A05E0EFQ38784950-58361713-9ADD-46CE-8A86-2F0FF71A8404
P2860
High-level primary CD8(+) T-cell response to human immunodeficiency virus type 1 gag and env generated by vaccination with recombinant vesicular stomatitis viruses.
description
2002 nî lūn-bûn
@nan
2002 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մարտին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
High-level primary CD8
@nl
High-level primary CD8(+) T-ce ...... vesicular stomatitis viruses.
@ast
High-level primary CD8(+) T-ce ...... vesicular stomatitis viruses.
@en
type
label
High-level primary CD8
@nl
High-level primary CD8(+) T-ce ...... vesicular stomatitis viruses.
@ast
High-level primary CD8(+) T-ce ...... vesicular stomatitis viruses.
@en
prefLabel
High-level primary CD8
@nl
High-level primary CD8(+) T-ce ...... vesicular stomatitis viruses.
@ast
High-level primary CD8(+) T-ce ...... vesicular stomatitis viruses.
@en
P2093
P2860
P1433
P1476
High-level primary CD8(+) T-ce ...... vesicular stomatitis viruses.
@en
P2093
Eric Pamer
Ingrid Leiner
John K Rose
Karl Haglund
Kristen Kerksiek
Linda Buonocore
P2860
P304
P356
10.1128/JVI.76.6.2730-2738.2002
P407
P577
2002-03-01T00:00:00Z